Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.

Mattsson, N., Axelsson, M., Haghighi, S., Malmeström, C., Wu, G., Anckarsäter, R., Sankaranarayanan, S., Andreasson, U., Fredrikson, S., Gundersen, A., Johnsen, L., Fladby, T., Tarkowski, A., Trysberg, E., Wallin, A., Anckarsäter, H., Lycke, J., Andersen, O., Simon, A.J., Blennow, K., Zetterberg, H.
Journal   Mult Scler.
Species  
Analytes Measured   APP
Matrix Tested   Cerebrospinal fluid (CSF)
Year   2009
Volume   15
Page Numbers   448-54
Application   Alzheimers
Abstract
BACKGROUND: Cell and animal experiments have shown that beta-site APP-cleaving enzyme 1 (BACE1) may be involved in myelination.

OBJECTIVE: Here, we assess the association of cerebrospinal fluid (CSF) BACE1 activity with multiple sclerosis (MS).

METHODS: BACE1 activity and levels of secreted amyloid precursor protein (APP) and amyloid-beta (Abeta) isoforms were analyzed in CSF from 100 patients with MS and 114 neurologically healthy controls. Patients with systemic lupus erythematosus (SLE), 26 with and 41 without cerebral engagement, were also included to enable comparisons with regards to another autoimmune disease. A subset of patients with MS and controls underwent a second lumbar puncture after 10 years.

RESULTS: MS patients had lower CSF BACE1 activity than controls (P = 0.03) and patients with cerebral SLE (P < 0.001). Patients with cerebral SLE had higher BACE1 activity than any other group (P < 0.05 for all comparisons). BACE1 activity correlated with the different amyloid markers in all study groups. BACE1 activity decreased over 10 years in the MS group (P = 0.039) and correlated weakly with clinical disease severity scores in an inverse manner.

CONCLUSIONS: These results suggest an involvement of BACE1 in the MS disease process.

View Publications

Related Products

sAPPα/sAPPβ Kit
APP | Human
Multiplex
Browse Our Products

By Analytes
By Applications
Search
Customer Service/Orders


Scientific/Technical Support


Instrument Support


Company Headquarters